Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transthyretin Amyloid Cardiomyopathy Treatment: An Updated Review

28 Aug 2025

Abstract excerpt

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive form of restrictive cardiomyopathy caused by the misfolding and deposition of transthyretin protein. What was once a condition that had little by way of treatment other than liver transplantation has now become a manageable disease due to revolutionary novel therapies. This review outlines therapeutic strategies aimed at halting or reversing disease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloidosis: Diagnosis, Treatment, Outcomes
Share to Cellular transport and secretion
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40943848
DOI: 10.3390/jcm14176089

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transthyretin Amyloid Cardiomyopathy Treatment: An Updated ReviewPMID 40943848Read ↗

Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathySemantic proximity Read ↗

Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trialsSemantic proximity Read ↗

Transthyretin Amyloid Cardiomyopathy–2025 Update: Current Diagnostic Approaches and Emerging Therapeutic OptionsSemantic proximity Read ↗

The transthyretin amyloidoses: advances in therapySemantic proximity Read ↗

A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.Semantic proximity Read ↗

RNA Targeting and Gene Editing Strategies for Transthyretin AmyloidosisSemantic proximity Read ↗

Treating hereditary transthyretin amyloidosis: Present & future challenges.Semantic proximity Read ↗

Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.Semantic proximity Read ↗

Disease-Modifying Treatments for Transthyretin Amyloidosis.Semantic proximity Read ↗

From stabilization to silencing in transthyretin amyloid cardiomyopathy: why sequencing should be treat-to-trajectory, not 'one-and-done'.Semantic proximity Read ↗

Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association.Semantic proximity Read ↗

Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.